Related Experiment Videos
The systematic study of drug therapy in rheumatoid arthritis
1Food and Drug Administration, Rockville, MD.
Abstract:
Important advances in therapeutics for rheumatoid arthritis (RA) will probably require coordination of the experience with new developing agents with an ongoing program of systematically collected open data, and formal controlled clinical trials to address key problematic issues. Controlled trials, despite formidable obstacles, not the least of which is the lack of satisfactory end points, are necessary because randomized treatment assignment is the only valid way to obtain results with a defined degree of certainty. A formal test of whether early aggressive intervention can arrest disease appears feasible. On the other hand, it does not now seem desirable to pursue a controlled, blinded study of RA over the longterm.
Insights
Advancing rheumatoid arthritis (RA) treatments requires combining new drug data with controlled clinical trials. While early intervention studies are feasible, long-term blinded RA trials are currently not advised.
Area of Science:
- Rheumatology
- Clinical Trial Design
- Pharmacological Research
Background:
- Rheumatoid arthritis (RA) therapeutics require novel approaches for significant advancement.
- Existing therapeutic strategies necessitate refinement through systematic data collection and rigorous evaluation.
- Challenges in RA treatment include defining satisfactory endpoints for clinical trials.
Purpose of the Study:
- To outline essential components for future therapeutic advances in rheumatoid arthritis.
- To discuss the necessity and feasibility of controlled clinical trials in RA research.
- To evaluate the suitability of long-term, blinded studies for RA.
Main Methods:
- Integration of real-world data from developing therapeutic agents.
- Implementation of systematically collected open data programs.
- Conducting formal controlled clinical trials with randomized treatment assignment.
Main Results:
- Controlled trials are essential for obtaining results with a defined degree of certainty, despite challenges.
- Randomized treatment assignment is the only valid method for reliable clinical trial outcomes.
- A formal test of early aggressive intervention to arrest RA disease progression appears feasible.
Conclusions:
- Future progress in RA therapeutics depends on combining new agent data with controlled trials.
- Long-term, controlled, and blinded studies for rheumatoid arthritis are not currently recommended.
- Focus should be on utilizing controlled trials to address key problematic issues and test interventions.